Riskpilot← Back to searchSign inGet full accessimmunAware ApS
APSActiveCVR 39189135Agern Alle 1Research and experimental development on natural sciences and engineering · NACE 7210Est. 20178 employeeshttps://immunaware.com
Revenue 2024
DKK 4,1M
-25% vs 2023
EBITDA margin
-14.1%
-128% vs 2023
Equity ratio
90.8%
Financial strength
Net profit 2024
DKK -757K
-158% vs 2023
| Revenue | DKK 4,1M | -25% |
| EBITDA | DKK -571K | -128% |
| Net profit | DKK -757K | -158% |
| Total assets | DKK 5,8M | -19% |
| Equity | DKK 5,3M | -15% |
| Employees | 8 | — |
Legal name
immunAware ApS
CVR number
39189135
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
19. december 2017
Share capital
DKK 50.000
Employees
8 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af hele direktionen i forening, eller af den administrerende direktør alene, eller af to direktører i forening.
Company purpose
Selskabet har til formål at udføre forsknings- og udviklingsaktiviteter med henblik på at tilbyde forskere i hele verden reagenser og service relateret til histocompatibilitets kompleks (MHC) klasse I og II molekyler, og at udføre sådanne aktiviteter, som direktionen skønsmæssigt måtte finde relaterende hertil.
Address
Agern Alle 1
Phone
+4593565551
Email
info@immunaware.com
Website
https://immunaware.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2.395 | 3.428 | 5.095 | 5.438 | 4.058 |
| Staff expenses | -869 | -1.764 | -2.968 | -3.405 | -4.629 |
| EBITDA | 1.526 | 1.664 | 2.127 | 2.033 | -571 |
| Depreciation & amort. | -7 | -184 | -184 | -325 | -421 |
| EBIT | 1.519 | 1.480 | 1.942 | 1.709 | -992 |
| Net financials | -45 | -16 | -44 | -55 | -13 |
| Profit before tax | 1.473 | 1.464 | 1.898 | 1.654 | -1.005 |
| Tax | 262 | 282 | 330 | 345 | -248 |
| Net profit | 1.211 | 1.183 | 1.567 | 1.309 | -757 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3.247 | 4.173 | 5.456 | 7.120 | 5.782 |
| Equity | 2.591 | 3.614 | 5.021 | 6.170 | 5.252 |
| Long-term debt | 37 | 37 | 0 | 0 | 0 |
| Short-term debt | 545 | 467 | 318 | 834 | 530 |
| Total debt | 582 | 504 | 318 | 834 | 530 |
EBITDA margin
-14.1%
This company
15.8%
Market median
-189% vs market
20202024
Equity ratio
90.8%
This company
38.2%
Market median
+138% vs market
20202024
Return on equity
-14.4%
This company
18.4%
Market median
-178% vs market
20202024
Net profit margin
-18.7%
This company
8.1%
Market median
-331% vs market
20202024
Asset turnover
0.70×
This company
1.12×
Market median
-38% vs market
20202024
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
AS Chief Executive Officer | Chief Executive Officer | 2018 |
TØ Management | Management | 2017 |
SB Management | Management | 2018 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 33.33–49.99% | 33.33–49.99% | 2017 | |
| Company | 25–33.32% | 25–33.32% | 2017 | |
| Company | 25–33.32% | 25–33.32% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PROSAL ApS
immunAware ApS Board members of immunAware ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anette Stryhn Buus | Chief Executive Officer | 0 companies |
| Thomas Østerbye | Management | 0 companies |
| Søren Buus | Management | 0 companies |